The decline comes as a growing number of Americans turn to GLP-1 drugs to lose weight. Gallup found that the use of these drugs specifically to lose weight (they’re also used to treat diabetes) has more than doubled from February 2024, when it was 5.8%, to 12.4% currently:
The study illustrates how quickly these drugs have made their way into the mainstream—and how valuable they are for drugmakers.
Meanwhile, other pharma companies are desperately trying to claw back market share of obesity drugs, which is expected to reach $150 billion by 2030.
